Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is associated with obesity. Bariatric surgery has been shown to be the most effective method for weight reduction. However, no conclusive data exists on the effects of weight reduction surgery on NAFLD. This study aimed to characterize liver histology, metabolic status, and liver function changes in patients who underwent bariatric surgery, before and after the weight-reduction procedure. This is a phase 1 report of a prospective cohort study of patients who underwent bariatric surgery. Biopsies were obtained at baseline (intraoperatively) and 3 months postoperatively. Clinical characteristics, biochemical profile, and histopathological data [steatosis, NAFLD activity score (NAS), hepatocyte ballooning, lobular inflammation, and degree of fibrosis] were obtained at each time point. Twenty-seven patients were included (9 men and 18 women), and the median age was 35 ± 8 years old. At baseline, 3 patients had dyslipidemia, 4 had diabetes, and 5 patients had hypertension, which did not change at follow-up. The average body mass index decreased from 44.6 ± 7.8 to 34.2 ± 6.3 kg/m2 at follow-up (P < 0.001). On histopathology, 12 of the 18 patients with preoperative steatosis (median score 2) had reduced steatosis scores postoperatively (P = 0.025); fibrosis (median score 1) was also reduced in 17 patients (P = 0.012), and NAS was decreased from 4 (3–5) to 2 (1–3) (P = 0.004). The changes in lobular inflammation and hepatocyte ballooning were not statistically significant on follow-up. The phase 1 results of this study described the histopathological changes following weight reduction surgery and suggested that hepatic steatosis, fibrosis, and NAFLD activity score were reduced 3 months after surgery. This clinical trial is financially supported by the National Plan for Science, Technology and Innovation Program grant number (11-MED1910-02).
Similar content being viewed by others
References
Dixon JB (2007) Surgical treatment for obesity and its impact on non-alcoholicsteatohepatitis. Clin Liver Dis 11:141–154
Kamada Y, Takehara T, Hayashi N (2008) Adipocytokines and liver disease. J Gastroenterol 43:811–822
Gholam PM, Kotler DP, Flancbaum LJ (2002) Liver pathology in morbidlyobese patients undergoing Roux-en-Y gastric bypass surgery. ObesSurg 12:49–51
Oliveira CP, Faintuch J, Rascovski A, Furuya CK Jr, Bastos Mdo S, Matsuda M et al (2005) Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD): Preliminary findings. ObesSurg 15:502–505
Frantzides CT, Carlson MA, Moore RE, Zografakis JG, Madan AK, Puumala S et al (2004) Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery. J Gastrointest Surg 8:849–855
Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR (2003) Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 138:1240–1244
Dixon JB, Bhathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100
Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G et al (2006) Long-term follow-up of patients with NAFLD andelevated liver enzymes. Hepatology 44:865–873
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M et al (2011) Prevalence of nonalcoholic fatty liver disease and nonalcoholicsteatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140:124–131
Sanyal AJNASH (2011) A global health problem. Hepatol Res 41:670–674
Physical status: The use and interpretation of anthropometry. Reportof a WHO Expert Committee. World Health Organ Tech Rep Ser1995;854:1–452
State-specific prevalence of obesity among adults–United States, 2005.Morb Mortal Wkly Rep 2006;55:985–8
Hossain P, Kawar B, El Nahas M (2007) Obesity and diabetes in the develo** world: a growing challenge. N Engl J Med 356:213–215
Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, Khan NB et al (2005) Obesity in Saudi Arabia. Saudi Med J 26:824–829
Angulo P, Lindor KD (2002) Non-alcoholic fatty liver disease. J GastroenterolHepatol 17(Suppl):S186–S190
Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E et al (2005) Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242:610–617
Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11:74–80
Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: mayo Clinic experiences with a hitherto unnamed disease. Mayo ClinProc 55:434–438
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321
Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C et al (2010) Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease ina hospital cohort and its association with anthropometric, biochemicaland sonographic characteristics. Int J Clin Exp Med 3:202–210
Paschos P, Paletas K (2009) Non alcoholic fatty liver disease and metabolicsyndrome. Hippokratia 13:9–19
Al-hamoudi W, El-Sabbah M, Ali S, Altuwaijri M, Bedewi M, Adam M et al (2012) Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study. Ann Saudi Med 32:288–292
Ruhl CE, Everhart JE (2003) Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the UnitedStates. Gastroenterology 124:71–79
Spaulding L, Trainer T, Janiec D (2003) Prevalence of non-alcoholicsteatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg 13:347–349
Moretto M, Kupski C, Mottin CC, Repetto G, Garcia Toneto M, Rizzolli J et al (2003) Hepatic steatosis in patients undergoing bariatric surgery andits relationship to body mass index and co-morbidities. Obes Surg 13:622–624
Silverman EM, Sapala JA, Appelman HD (1995) Regression of hepatic steatosisin morbidly obese persons after gastric bypass. Am J Clin Pathol 104:23–31
Dixon JB, Bhathal PS, Hughes NR, O’Brien PE (2004) Nonalcoholic fatty liverdisease: improvement in liver histological analysis with weight loss. Hepatology 39:1647–1654
Padwal RS (2005) Characteristics of patients undergoing bariatric surgery inCanada. Obes Res 13:2052–2054
Trus TL, Pope GD, Finlayson SR (2005) National trends in utilization andoutcomes of bariatric surgery. Surg Endosc 19:616–620
Dixon JB, Anderson M, Cameron-Smith D, O’Brien PE (2004) Sustained weightloss in obese subjects has benefits that are independent of attainedweight. Obes Res 12:1895–1902
MacDonald KGJ, Long SD, Swanson MS, Brown BM, Morris P, Dohm GL et al (1997) The gastric bypass operation reduces the progression andmortality of non-insulin-dependent diabetes mellitus. J GastrointestSurg 1:213–220
Kashyap SR, Daud S, Kelly KR, Gastaldelli A, Win H, Brethauer S,et al. Acute effects of gastric bypass versus gastric restrictivesurgery on beta-cell function and insulinotropic hormones inseverely obese patients with type 2 diabetes. Int J Obes (Lond)2010;34:462–71
Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N et al (2006) Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130:1564–1572
Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H et al (2010) Anti-inflammatory effects of excessive weight loss: potentsuppression of adipose interleukin 6 and tumour necrosis factor alphaexpression. Gut 59:1259–1264
Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH (2005) Roux-en-Y gastric bypass improves liver histology in patients withnon-alcoholic fatty liver disease. Obes Res 13:1180–1186
Furuya CK Jr, de Oliveira CP, de Mello ES, Faintuch J, Raskovski A, Matsuda M et al (2007) Effects of bariatric surgery on nonalcoholic fatty liverdisease: preliminary findings after 2 years. J Gastroenterol Hepatol 22:510–514
Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R et al (2009) Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137:532–540
Papadia F, Marinari GM, Camerini G, Adami GF, Murelli F, Carlini F et al (2003) Short-term liver function after biliopancreatic diversion. Obes Surg 13:752–755
Keshishian A, Zahriya K, Willes EB (2005) Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after6 months. Obes Surg 15:1418–1423
Burza MA, Romeo S, Kotronen A, Svensson PA, Sjöholm K, Torgerson JS, Lindroos AK, Sjöström L, Carlsson LM, Peltonen M (2013) Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS ONE 8(3):e60495
Acknowledgments
This clinical trial is financially supported by The National Plan for Science, Technology and Innovation Program Grant Number (11-MED1910-02).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
Authors T. Aldoheyan, M. Hassanian, A. Al-Mulhim, A. Al-Sabhan, S. Al-Amro, F. Bamehriz and H. Al Khalid have no conflicts of interest.
Additional information
Tamadar Aldoheyan and Mazen Hassanian have equally shared first co-authorship.
Rights and permissions
About this article
Cite this article
Aldoheyan, T., Hassanain, M., Al-Mulhim, A. et al. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc 31, 1142–1147 (2017). https://doi.org/10.1007/s00464-016-5082-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-016-5082-8